Gilles Troché

Gilles Troché

Auto-generated profile, based on publicly available information

Gilles Troché

Centre Hospitalier de Versailles

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2002 in JAMA
Verified
Journal Article
Closed access
PDF file
DADjillali Annane
Djillali Annane
VSVéronique Sébille
Véronique Sébille
CCClaire Charpentier
Claire Charpentier
PBPierre-Edouard Bollaert
Pierre-Edouard Bollaert
BFBruno François
Bruno François
EBEric Bellissant
Eric Bellissant
Research from JAMA — Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock — ContextSeptic shock may be associated with relative adrenal insufficiency. Thus, a replacement therapy of low doses of corticosteroids has been proposed to treat septic shock.ObjectiveTo assess whether low doses of corticosteroids improve 28-day survival in patients with septic shock and relative adrenal insufficiency.Design and SettingPlacebo-controlled, randomized, double-blind, parallel-group trial performed in 19 intensive care units in France from October 9, 1995, to February 23, 1999.PatientsThree hundred adult patients who fulfilled usual criteria for septic shock were enrolled after undergoing a short corticotropin test.InterventionPatients were randomly assigned to receive either hydrocortisone (50-mg intravenous bolus every 6 hours) and fludrocortisone (50-µg tablet once daily) (n = 151) or matching placebos (n = 149) for 7 days.Main Outcome MeasureTwenty-eight-day survival distribution in patients with relative adrenal insufficiency (nonresponders to the corticotropin test).ResultsOne patient from the corticosteroid group was excluded from analyses because of consent withdrawal. There were 229 nonresponders to the corticotropin test (placebo, 115; corticosteroids, 114) and 70 responders to the corticotropin test (placebo, 34; corticosteroids, 36). In nonresponders, there were 73 deaths (63%) in the placebo group and 60 deaths (53%) in the corticosteroid group (hazard ratio, 0.67; 95% confidence interval, 0.47-0.95; P = .02). Vasopressor therapy was withdrawn within 28 days in 46 patients (40%) in the placebo group and in 65 patients (57%) in the corticosteroid group (hazard ratio, 1.91; 95% confidence interval, 1.29-2.84; P = .001). There was no significant difference between groups in responders. Adverse events rates were similar in the 2 groups.ConclusionIn our trial, a 7-day treatment with low doses of hydrocortisone and fludrocortisone significantly reduced the risk of death in patients with septic shock and relative adrenal insufficiency without increasing adverse events.

23 February 2000 in JAMA
Verified
Journal Article
Open access
PDF file
DADjillali Annane
Djillali Annane
VSVéronique Sébille
Véronique Sébille
GTGilles Troché
Gilles Troché
JRJean-Claude Raphaël
Jean-Claude Raphaël
PGPhilippe Gajdos
Philippe Gajdos
EBEric Bellissant
Eric Bellissant
Septic shock remains the most common cause of death in noncoronary intensive care units (ICUs).1 To tackle this problem, numerous anti-inflammatory therapies have been tested during the past decade, but all of them have been unable to improve survival in patients with severe sepsis.2 Thus, there is an urgent need to better characterize septic patients with the worst outcome. Several clinical prognostic factors have already been identified (ie, preexisting underlying disease, presence of organ dysfunction, and severity of illness scores).3 Moreover, the hormonal profile has been suggested to be a valid predictor of outcome in critically ill patients.4 However, a pathophysiologic derangement that could help identify a group of patients who might benefit from a particular treatment has not been characterized yet.

1 August 2007 in The Lancet
Verified
Journal Article
Closed access
DAdjillali Annane
djillali Annane
PVPhilippe Vignon
Philippe Vignon
ARAlain Renault
Alain Renault
PBPierre-Edouard Bollaert
Pierre-Edouard Bollaert
CCClaire Charpentier
Claire Charpentier
EBEric Bellissant
Eric Bellissant

15 December 2012 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
JTJean-François Timsit
Jean-François Timsit
OMolivier mimoz
olivier mimoz
BMBruno Mourvillier
Bruno Mourvillier
BSBertrand Souweine
Bertrand Souweine
MGMaïté Garrouste-Orgeas
Maïté Garrouste-Orgeas
JLJean-Christophe Lucet
Jean-Christophe Lucet
Rationale: Most vascular catheter-related infections (CRIs) occur extraluminally in patients in the intensive care unit (ICU). Chlorhexidine-impregnated and strongly adherent dressings may decrease catheter colonization and CRI rates. Objectives: To determine if chlorhexidine-impregnated and strongly adherent dressings decrease catheter colonization and CRI rates. Methods: In a 2:1:1 assessor-masked randomized trial in patients with vascular catheters inserted for an expected duration of 48 hours or more in 12 French ICUs, we compared chlorhexidine dressings, highly adhesive dressings, and standard dressings from May 2010 to July 2011. Coprimary endpoints were major CRI with or without catheter-related bloodstream infection (CR-BSI) with chlorhexidine versus nonchlorhexidine dressings and catheter colonization rate with highly adhesive nonchlorhexidine versus standard nonchlorhexidine dressings. Catheter-colonization, CR-BSIs, and skin reactions were secondary endpoints. Measurements and Main Results: A total of 1,879 patients (4,163 catheters and 34,339 catheter-days) were evaluated. With chlorhexidine dressings, the major-CRI rate was 67% lower (0.7 per 1,000 vs. 2.1 per 1,000 catheter-days; hazard ratio [HR], 0.328; 95% confidence interval [CI], 0.174–0.619; P = 0.0006) and the CR-BSI rate 60% lower (0.5 per 1,000 vs. 1.3 per 1,000 catheter-days; HR, 0.402; 95% CI, 0.186–0.868; P = 0.02) than with nonchlorhexidine dressings; decreases were noted in catheter colonization and skin colonization rates at catheter removal. The contact dermatitis rate was 1.1% with and 0.29% without chlorhexidine. Highly adhesive dressings decreased the detachment rate to 64.3% versus 71.9% (P < 0.0001) and the number of dressings per catheter to two (one to four) versus three (one to five) (P < 0.0001) but increased skin colonization (P < 0.0001) and catheter colonization (HR, 1.650; 95% CI, 1.21–2.26; P = 0.0016) without influencing CRI or CR-BSI rates. Conclusions: A large randomized trial demonstrated that chlorhexidine-gel–impregnated dressings decreased the CRI rate in patients in the ICU with intravascular catheters. Highly adhesive dressings decreased dressing detachment but increased skin and catheter colonization. Clinical trial registered with www.clinicaltrials.gov (NCT01189682).

14 September 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SLStephane Legriel
Stephane Legriel
OSOlivier Schraub
Olivier Schraub
EAElie Azoulay
Elie Azoulay
PHPhilippe Hantson
Philippe Hantson
EMEric Magalhaes
Eric Magalhaes
FPFernando Pico
Fernando Pico
Few outcome data are available about posterior reversible encephalopathy syndrome (PRES). We studied 90-day functional outcomes and their determinants in patients with severe PRES. 70 patients with severe PRES admitted to 24 ICUs in 2001–2010 were included in a retrospective cohort study. The main outcome measure was a Glasgow Outcome Scale (GOS) of 5 (good recovery) on day 90. Consciousness impairment was the most common clinical sign, occurring in 66 (94%) patients. Clinical seizures occurred in 57 (81%) patients. Median mean arterial pressure was 122 (105–143) mmHg on scene. Cerebral imaging abnormalities were bilateral (93%) and predominated in the parietal (93%) and occipital (86%) white matter. Median number of brain areas involved was 4 (3–5). Imaging abnormalities resolved in 43 (88%) patients. Ischaemic and/or haemorrhagic complications occurred in 7 (14%) patients. The most common causes were drug toxicity (44%) and hypertensive encephalopathy (41%). On day 90, 11 (16%) patients had died, 26 (37%) had marked functional impairments (GOS, 2 to 4), and 33 (56%) had a good recovery (GOS, 5). Factors independently associated with GOS<5 were highest glycaemia on day 1 (OR, 1.22; 95%CI, 1.02–1.45, p = 0.03) and time to causative-factor control (OR, 3.3; 95%CI, 1.04–10.46, p = 0.04), whereas GOS = 5 was associated with toxaemia of pregnancy (preeclampsia/eclampsia) (OR, 0.06; 95%CI, 0.01–0.38, p = 0.003). By day 90 after admission for severe PRES, 44% of survivors had severe functional impairments. Highest glycaemia on day 1 and time to causative-factor control were strong early predictors of outcomes, suggesting areas for improvement.

6 February 2004 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
MGMaité Garrouste-Orgeas
Maité Garrouste-Orgeas
GTGilles Troché
Gilles Troché
EAElie Azoulay
Elie Azoulay
ACAntoine Caubel
Antoine Caubel
ALArnaud de Lassence
Arnaud de Lassence
JTJean-François Timsit
Jean-François Timsit